"10.1371_journal.pone.0116227","plos one","2015-01-24T00:00:00Z","Marjolein A van Maanen; Roger L Papke; Frieda A Koopman; Jessica Koepke; Lisette Bevaart; Roger Clark; Diana Lamppu; Daniel Elbaum; Gregory J LaRosa; Paul P Tak; Margriet J Vervoordeldonk","Department of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands; Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida, United States of America; Arthrogen BV, Amsterdam, The Netherlands; Cornerstone Therapeutics, Inc., Cary, North Carolina, United States of America; DEC Associates, LLC, Newton, Massachusetts, United States of America","Conceived and designed the experiments: MAvM RLP GJLR PPT MJV. Performed the experiments: MAvM RLP JK LB RC DL. Analyzed the data: MAvM RLP FK GJLR PPT MJV. Contributed reagents/materials/analysis tools: DE RC GJLR. Wrote the paper: MAvM RLP FK DE GJLR PPT MJV.","This study was funded in part by a research award from Cornerstone Therapeutics Inc. PPT received research support from SetPoint Medical and Critical Therapeutics. Coauthors Roger Clark, Diana Lamppu and Gregory J. LaRosa were employed by Cornerstone Therapeutics, Inc. during the course of the study. Co-authors Jessica Koepke, Lisette Bevaart and Margriet J. Vervoordeldonk are employed by Arthrogen BV. Co-author Daniel Elbaum is employed by DEC Associates, LLC. Roger Clark and Dan Elbaum hold a patent on NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF; variables of piperazine derivatives can act as agonists of the alpha7 nAChR (WO2007146066). The current controller of the patent is Targacept. Targacept licensed the patent from Cornerstone, which before that licensed it from Critical Therapeutics (original applier). This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","01","Marjolein A van Maanen","MAVM",11,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
